Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 17395 pages

Showing 12351 - 12400


Julienne Bower, PhD, Named Professor of Psychobiology in Cousins Center for Psychoneuroimmunology at UCLA

The Cousins Center for Psychoneuroimmunology at the University of California, Los Angeles (UCLA) Semel Institute for Neuroscience and the UCLA Jonsson Comprehensive Cancer Center (JCCC) announced that Julienne Bower, PhD, Co-Director of the JCCC Patients and Survivors Program, Professor of...

The Building Block of Life, Brick by Brick

BookmarkTitle: The Gene: An Intimate HistoryAuthor: Siddhartha Mukherjee, MDPublisher: ScribnerPublication date: May 2016Price: $32.00; hardcover, 608 pagesOn February 28, 1953, James Watson and Francis Crick entered The Eagle, a favorite watering hole for researchers working at the University of...

lung cancer

David LeDuc Named Executive Director of Addario Lung Cancer Foundation

The Bonnie J. Addario Lung Cancer Foundation (ALCF) has announced that it has appointed David LeDuc as its new Executive Director. Mr. LeDuc most recently served as the Senior Director of Strategic Alliances for the Addario Lung Cancer Medical Institute (ALCMI), a partner foundation to ALCF, where ...

palliative care

Integrating Early Palliative Medicine Into Oncology Care to Improve Patients’ Quality of Life

At the 2015 Palliative Care in Oncology Symposium in Boston, Vicki Jackson, MD, MPH, Chief in the Division of Palliative Care and Geriatrics at Massachusetts General Hospital, Co-Director of the Harvard Center for Palliative Care, and Associate Professor of Medicine at Harvard Medical School,...

ASH Commits $3 Million Annually to Help Preserve Critical Blood Disease Research

With a $3 million annual commitment to support promising blood disease research amid limited National Institutes of Health (NIH) funding, the American Society of Hematology (ASH) has announced the formal establishment of the ASH Bridge Grant program after an extended 4-year pilot study. ASH also...

FDA Approves Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C Virus Infection

The U.S. Food and Drug Administration (FDA) approved Epclusa (sofosbuvir at 400 mg/velpatasvir at 100 mg) on June 28, 2016, to treat adult patients with chronic hepatitis C virus both with and without cirrhosis. For patients with moderate to severe cirrhosis (decompensated cirrhosis),...

gynecologic cancers

FDA Approves First HPV Test for Use With SurePath Preservative Fluid

On July 7, 2016, the U.S. Food and Drug Administration (FDA) approved the Roche cobas HPV Test as the first test for human papillomavirus (HPV) that can be used with cervical cells obtained for a Papanicolau (Pap) test and collected in SurePath Preservative Fluid. The FDA approves HPV tests to be...

leukemia

Juno Therapeutics to Resume JCAR015 Phase II ROCKET Trial After FDA Clinical Hold

Juno Therapeutics, Inc., announced on July 12, 2016, that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the phase II clinical trial of JCAR015 (known as the ROCKET trial; clinicaltrials.gov identifier NCT02535364) in adult patients with relapsed or refractory B-cell...

NCCN Imaging Appropriate Use Criteria to Be Integrated Into National Decision Support Company’s CareSelect Imaging

The National Comprehensive Cancer Network® (NCCN) is collaborating with National Decision Support Company (NDSC) to integrate the NCCN Imaging Appropriate Use Criteria (AUC) into NDSC’s CareSelect Imaging to allow for access to imaging recommendations, adapted from the NCCN Clinical Practice...

Maryland Proton Treatment Center Appoints Charles B. Simone II, MD, New Medical Director

Charles B. Simone II, MD, has been named the new Medical Director of the Maryland Proton Treatment Center (MPTC). Dr. Simone will begin work in November 2016. As Medical Director, Dr. Simone will continue to define and implement processes ensuring that MPTC is integrated into the radiation...

NCI Awards $12 Million for Multi-Institution Breast Cancer Genetics Study

A large study headed by researchers from the Keck School of Medicine of the University of Southern California (USC), Vanderbilt University, and Boston University received $12 million in funding to examine why African American women die at a higher rate from breast cancer and have more aggressive...

Epithelial Cells on the Tail Fin of Genetically Engineered Zebrafish

Image depicts hundreds of live cells from a tiny bit of skin on the tail fin of a genetically engineered adult zebrafish. The cells have been labeled with a new fluorescent imaging tool called Skinbow. It uniquely color codes cells by getting them to express genes encoding red, green, and blue...

issues in oncology

New Analysis Shows Advertising by U.S. Cancer Centers Has Soared Over Past Decade

American cancer centers promoting their services dramatically increased their advertising spending from 2005 to 2014, with the bulk of the spending by for-profit organizations, according to the results of a study published by Vater et al in JAMA Internal Medicine.1 Small Percentage Responsible for...

issues in oncology

Actively Recruiting Clinical Trials Focused on the Role of Obesity in Cancer

Study Title: A Pilot Study of a Protein-Sparing Modified Fast for Weight Loss in Obese Endometrial Cancer Survivors Study Type: Pilot/interventional/single-group assignment Study Sponsor and Collaborators: Case Comprehensive Cancer Center, National Cancer Institute  Purpose: To study whether the...

2016 - 2017 Oncology Meetings

AUGUST The 33rd World Congress of Internal Medicine (WCIM)August 22-25 • Bali, IndonesiaFor more information: www.wcimbali2016.org 16th World Congress on Cancers of the SkinAugust 31-September 3 • Vienna, Austria For more information: www.wccs2016.com 12th National Lymphedema Network International...

13 Mid-Career Clinical Investigators Receive 2016 NCI Cancer Clinical Investigator Team Leadership Award

At the National Cancer Institute (NCI) Clinical Trials and Translational Research Advisory Committee (CTAC) meeting held on July 13, 2016, 13 recipients were presented with the 2016 NCI Cancer Clinical Investigator Team Leadership Award (CCITLA). The award recognizes and supports outstanding...

OmniSeq Receives New York CLEP Approval for 144-Gene Comprehensive Panel, Partners With Cure Forward

OmniSeq, a subsidiary of Roswell Park Cancer Institute, received New York State Clinical Laboratory Evaluation Program (CLEP) approval for its OmniSeq Comprehensive panel, a 144-gene, pan-cancer, next-generation sequencing tumor-profiling diagnostic panel to guide oncology treatment...

Andrew Olshan, PhD, Elected President of the Society for Epidemiologic Research

Andrew Olshan, PhD, Associate Director of Population Sciences and Co-Leader of the Epidemiology Program at UNC Lineberger Comprehensive Cancer Center, has been elected President of the Society for Epidemiologic Research, the oldest and largest general epidemiology society in North America. He will ...

Abhishek Aphale, MD, Joins Department of Dermatology at Fox Chase Cancer Center

Abhishek Aphale, MD, has been appointed Assistant Professor of Dermatology at Fox Chase Cancer Center. Dr. Aphale earned his medical degree from the Robert Wood Johnson Medical School of Rutgers University. He completed his residency training at the University of Michigan and a Procedural...

Rajeswari Nagarathinam, MD, Joins Department of Pathology at Fox Chase Cancer Center

Rajeswari Nagarathinam, MD, has joined the Department of Pathology at Fox Chase Cancer Center, focusing on both surgical pathology and cytopathology. Dr. Nagarathinam is currently completing a surgical oncologic pathology fellowship at Fox Chase. Dr. Nagarathinam is a licensed, board-certified...

issues in oncology
geriatric oncology

Safety Concerns Weigh Heavily in Elderly Patients With Cancer

Active pharmacovigilance in detecting and assessing the safety signals related to drugs and devices, and disseminating those findings to relevant stakeholders, is an important component in delivering safe, high-quality care in the cancer setting. To reach a better understanding of this issue,...

breast cancer

Ribociclib Receives FDA Breakthrough Therapy Designation for Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ribociclib in combination with letrozole for the treatment of hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Ribociclib...

prostate cancer

Androgen-Deprivation Therapy May Increase Mortality in African American Men With Favorable-Risk Prostate Cancer

In a retrospective study analyzing patients' medical records, researchers at Brigham and Women's Hospital (BWH) found that race significantly affected longevity by increasing the likelihood of death after receiving androgen-deprivation therapy. These findings were published by Kovtun et al in...

kidney cancer

Metabolic Gene-Expression Profile May Identify Kidney Cancer Patients Unlikely to Benefit From Nivolumab

Renal cell carcinomas (RCC) positive for the protein programmed death ligand 1 (PD-L1) from patients who did not respond to treatment with the anti–PD-1 therapeutic nivolumab (Opdivo) had significantly higher expression of genes associated with metabolism, compared with PD-L1–positive...

lymphoma

Is Post-Transplantation Cyclophosphamide Disruptive Technology?

There was a time when transplantation across human leukocyte antigen (HLA) barriers was fraught with so much difficulty that many thought it was impossible and we should stop trying. However, most patients do not have an HLA-matched sibling donor, and death was therefore certain if they had a...

issues in oncology

Effects of the Global Economic Crisis on Cancer Care

The global economic crisis beginning in 2008 was associated with substantial public health effects, especially with respect to mental health.1–3 Nevertheless, there is also evidence of a paradoxical association between recessions and reduced all-cause mortality, in part because of reductions in...

10 New ASTRO Fellows Named in 10th Anniversary of FASTRO Designation

Ten distinguished members of the American Society for Radiation Oncology (ASTRO) have been named ASTRO Fellows, in the 10th anniversary year that the designation has been awarded. The 2016 class of Fellows will be recognized at an awards ceremony during ­ASTRO’s 58th Annual Meeting, to be held...

colorectal cancer

Anti–Interleukin-1 Alpha Antibody MABp1 Improves Outcomes Significantly Over Placebo in Advanced Colorectal Cancer

A novel anti–interleukin-1 alpha (IL-1α) antibody has shown a significant impact on symptoms and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data presented by Hickish et al at the European Society for Medical Oncology’s 18th World...

gastrointestinal cancer

Chemoradiotherapy After Surgery for Gastric Cancer Shows Similar Outcomes to Postoperative Chemotherapy

Postoperative treatment intensification with chemoradiotherapy does not achieve better outcomes when compared with postoperative chemotherapy in patients with gastric cancer who have already undergone preoperative chemotherapy, according to phase III data presented by Marcel Verheij, MD, PhD, et...

hepatobiliary cancer

Phase III RESORCE Study Data Show Regorafenib Improves Overall Survival in Previously Treated Patients With Unresectable Liver Cancer

Results from the phase III RESORCE trial show that regorafenib (Stivarga) tablets achieved a median overall survival improvement in patients with unresectable hepatocellular carcinoma that progressed after treatment with sorafenib (Nexavar) tablets. The study, presented by Jordi Bruix, MD, et al...

colorectal cancer

Anti–PD-L1 Immunotherapy Shows Response in Microsatellite-Stable Metastatic Colorectal Cancer in Combination With MEK Inhibition

Anti–PD-L1 (programmed death ligand 1) immunotherapy may achieve a response in patients with microsatellite-stable metastatic colorectal cancer if combined with a MEK inhibitor, according to phase I data presented at the European Society for Medical Oncology (ESMO) 18th World Congress on...

head and neck cancer
issues in oncology

New Study Finds Increase in Imaging After Thyroid Cancer Treatment Identifies Recurrence but May Not Improve Survival

More imaging after thyroid cancer treatment identifies recurrence, but it does not always improve survival, a new study published by Banerjee et al in The BMJ suggests. Researchers from the University of Michigan Comprehensive Cancer Center looked at 28,220 patients diagnosed with...

breast cancer

African American Women More Likely to Choose Autologous Breast Reconstruction Over Implant-Based Reconstruction

African American women undergoing mastectomy for breast cancer are more likely than white women to undergo autologous breast reconstruction using their own tissue, rather than implant-based reconstruction, reported Sharma et al in Plastic and Reconstructive Surgery. “African American race...

lung cancer

AAPM 2016: Somatic Mutations and PET-Based Radiomic Features in Non–Small Cell Lung Cancer

A cutting-edge method of extracting big data from positron-emission tomography (PET) images can provide additional information to quantify lung tumors caused by a genetic mutation. This information could help guide the most effective treatment, suggest findings of a study of nearly 350 patients...

breast cancer

Social Media Engagement May Be Linked to More Satisfaction With Breast Cancer Treatment Decisions

Women who engaged on social media after a breast cancer diagnosis expressed more deliberation about their treatment decision and more satisfaction with the path they chose, a new study from the University of Michigan Comprehensive Cancer Center finds. Findings were published by Wallner et al in...

prostate cancer

Hypofractionation May Be Poised to Become New Standard of Care for Prostate Cancer

There has been an ongoing debate about which type of radiation therapy is preferable in the treatment of localized prostate cancer: hypofractionation (larger fractions given over 4–5 weeks) or conventional radiotherapy (given over 8–9 weeks). A new study presented at the 2016 ASCO Annual Meeting...

cost of care

ASCO Plenary Studies: Assessing the ‘Value’ of New Treatments

At the 2016 ASCO Annual Meeting, studies presented at the Plenary Session gave attendees new treatment strategies to employ back home. But in the emerging push to contain the cost of new cancer treatments, do the four interventions fit within the new “value framework” for oncology? Deborah Schrag, ...

breast cancer

Insurance, Distance to Care Can Be Barriers to Breast Reconstruction

Women were less likely to have breast reconstruction surgery after mastectomy if they had Medicaid or Medicare rather than private insurance or if they lived 10 or more miles from a plastic surgeon’s office, a University of North Carolina (UNC) Lineberger Comprehensive Cancer Center study has ...

breast cancer

Sampling Method Used for New Breast Cancer Tests May Lead to Underestimation of Risk

Not only is breast cancer more than one disease, but a single breast cancer tumor can vary within itself, a finding that University of Pittsburgh Cancer Institute (UPCI) researchers discovered has the potential to lead to very different patient treatment plans depending on the tumor sample and...

gastroesophageal cancer

Association Between Germline Mutation in VSIG10L and Barrett's Esophagus/Esophageal Cancer

Researchers at University Hospitals Case Medical Center have discovered that a rare genetic mutation is associated with susceptibility to familial Barrett's esophagus and esophageal cancer. The findings were published by Fecteau et al in JAMA Oncology. Amitabh Chak, MD, of University Hospitals...

prostate cancer

Sociodemographic and Clinical Predictors of Switching to Active Treatment From Observational Management in Low-Risk Prostate Cancer

Although active surveillance for patients with low-risk prostate cancer has become an increasingly acceptable strategy for disease management, many men opt for definitive therapies such as radical prostatectomy or radiation therapy. A new study of more than 2,200 patients with low-risk prostate...

leukemia

Study Evaluates Chronic Graft-vs-Host Disease Burden and Complications in Patients Receiving Bone Marrow Transplants

A University of Colorado Cancer Center study compared outcomes of leukemia patients receiving bone marrow transplants from 2009 to 2014, finding that 3 years post transplant, the incidence of severe chronic graft-vs-host disease was significantly higher in patients who had received transplants from ...

cns cancers

Effect of Radiosurgery Alone vs Radiosurgery Plus WBRT on Cognitive Function in Patients With Brain Metastases

Physicians from Carolinas HealthCare System's Neurosciences Institute and Levine Cancer Institute are among the authors of a study published by Brown et al in JAMA. The study showed how among patients with one to three brain metastases, the use of stereotactic radiosurgery (SRS) alone, compared...

skin cancer

USPSTF Issues Final Recommendation Statement on Screening for Skin Cancer

The U.S. Preventive Services Task Force (USPSTF) has concluded that the current evidence is insufficient to assess the balance of benefits and harms of visual skin examination by a clinician to screen for skin cancer in asymptomatic adults. The report was published in JAMA. This is an “I...

issues in oncology

Delirium Frequent and Underdiagnosed Among Advanced Cancer Patients Presenting to an Emergency Department

A new study indicates that delirium is relatively frequent and underdiagnosed by physicians in patients with advanced cancer visiting the emergency department. Delirium was similarly common among older and younger patients, which suggests that in the setting of advanced cancer, all patients should...

multiple myeloma

FDA Grants Breakthrough Therapy Designation for Daratumumab in Combination With Standard of Care for Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the immunotherapy daratumumab (Darzalex) in combination with lenalidomide (Revlimid) and dexamethasone, or bortezomib (Velcade) and dexamethasone, for the treatment of patients with multiple myeloma who have ...

prostate cancer

Patients With Low-Risk Prostate Cancer on Active Surveillance Experience Good Quality of Life

Active surveillance has become an increasingly important alternative to surgery, chemotherapy, or radiation treatment for men diagnosed with low-risk prostate cancer. However, what is the impact of active surveillance on health-related quality of life in patients selected or opting for this...

issues in oncology

Some Adolescent Survivors of Childhood Cancer May Benefit From More Comprehensive Mental Health Screening

Most adolescent survivors of childhood cancer have no reported psychological symptoms, but an analysis led by St. Jude Children's Research Hospital found that those who do often have multiple symptoms and distinct symptom profiles. The findings, published by Krull et al in the Journal of Clinical...

health-care policy

The National Cancer Moonshot Lifts Off

Just 6 months after President Barack Obama announced the establishment of a National Cancer Moonshot Initiative to accelerate the pace of research discoveries, improve patient access and care, and encourage data-sharing, dozens of new initiatives to accomplish those and other goals were rolled out...

The Henry and Marilyn Taub Foundation Gives $1 Million to Pancreatic Cancer Action Network for Immunotherapy Research

The Henry and Marilyn Taub Foundation has presented a gift of $1 million to support the Shirley Sadoff Pancreatic Cancer Action Network Research Acceleration Network 2 Grant. The grant will support a large, multicenter phase II clinical trial studying an immunotherapeutic approach in patients with...

Advertisement

Advertisement




Advertisement